Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2010

View Archived Issues

Novel mixed-format HIV vaccine shows promise in phase I trial in healthy adult volunteers

Antares and Population Council report phase II trial results for transdermal contraceptive gel

Savient presents update on BLA resubmission for Krystexxa for chronic gout

Novartis launches Fanapt in the U.S. for schizophrenia

PhotoMedex and Galderma Laboratories sign copromotion agreement for Metvixia for AK

Ablynx generates Nanobodies against an ion channel and CXCR4 receptor

Amarin initiates enrollment into MARINE and ANCHOR phase III trials of AMR-101

BioMarin initiates phase I clinical trial of SMT-C1100 for Duchenne muscular dystrophy

Inhibitex presents update on development of SA3Ag vaccine, FV-100 and INX-189

NicOx and Topigen terminate collaboration on anti-inflammatory drug TPI-1020

ReNeuron presents regulatory update on ReN-001 and ReN-009 stem cell therapies

Preclinical findings encourage clinical evaluation of mAb 1339 in multiple myeloma

Milk thistle extract silibinin shows potent activity in in patients with hepatitis C

Synthetic platelets show promise in rat model of major trauma

INX-189 displays potent inhibitory activity against HCV in vitro

Boehringer Ingelheim identifies novel MMP-13 inhibitors as potential arthritis therapeutics

Korea Research Institute of Chemical Technology discloses protein kinase inhibitors for cancer

Novel liver X receptor ligands disclosed by Organon Laboratories as atherosclerosis treatments

Array BioPharma describes novel kinase-inhibiting pyrrolopyridines as oncolytic agents

TaiGen Biotechnology claims novel HCV protease inhibitors

Facet Biotech enrolls first patient in phase II trial of elotuzumab in multiple myeloma

4SC treats first patient in a phase II trial of resminostat in Hodgkin's lymphoma

Cytokinetics reports data from phase I trial of skeletal muscle activator CK-2017357

Pluristem Therapeutics reports interim phase I results on PLX-PAD for critical limb ischemia

KemPharm presents encouraging results from phase I trial of KP-106 for ADHD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...